All In Biotech

Free tool

FAERS Monitor: Zokinvy

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213969 or its brand name (Zokinvy, Lonafarnib). Reports on generic versions are filed under their own applications.

Reports

78

Serious

42

54% of reports

Hospitalization

25

Death reported

12

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product dose omission issue23
  • diarrhoea16
  • vomiting12
  • death4
  • headache4
  • abdominal pain upper3
  • asthenia3
  • cardiac operation3
  • fatigue3
  • malaise3
  • nausea3
  • product supply issue3
  • pyrexia3
  • abdominal discomfort2
  • anaemia2

Reports by year received

View as table
YearReports
20041
20051
20061
20073
20085
20091
20121
20133
20142
20191
20203
202121
202215
20239
20247
20252
20262

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,081 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product supply issueSignal3113.437.4231
cardiac operationSignal394.131.0191
product dose omission issueSignal2321.115.0426
vomitingSignal126.94.156
diarrhoeaSignal166.74.374
abdominal pain upper33.91.34
abdominal discomfort23.20.81
anaemia22.80.71
pyrexia32.30.81
asthenia32.20.71
malaise31.80.60
headache41.70.71
death41.30.50
fatigue31.00.30
nausea31.00.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.